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Background: Copy-number gain of the oncostatin-M receptor (OSMR) occurs frequently in cervical squamous cell carcinoma
(SCC) and is associated with adverse clinical outcome. We previously showed that OSMR overexpression renders cervical SCC
cells more sensitive to the major ligand oncostatin-M (OSM), which increases migration and invasion in vitro. We hypothesised that
a major contribution to this phenotype would come from epithelial–mesenchymal transition (EMT).
Methods: We performed a comprehensive integrated study, involving in vitro cell line studies, in vivo animal models and
numerous clinical samples from a variety of anatomical sites.
Results: In independent sets of cervical, head/neck and lung SCC tissues, OSMR expression levels correlated with multiple EMT-
associated phenotypic markers and transcription factors. OSM treatment of OSMR overexpressing cervical SCC cells produced
consistent EMT changes and increased tumour sphere formation in suspension culture. In a mouse model, OSMR overexpressing
SCC cells treated with OSM showed significant increases in lung colonisation. The biological effects of exogenous OSM were
mirrored by highly significant adverse overall survival in cervical SCCs with OSMR overexpression (N¼ 251).
Conclusions: OSM:OSMR interactions are able to induce EMT, increased cancer stem cell-like properties and enhanced lung
colonisation in SCC cells. These changes are likely to contribute to the highly significant adverse outcome associated with OSMR
overexpression in cervical SCCs.
There are B300 000 deaths from cervical carcinoma worldwide
each year (Forman et al, 2012). Most cases are squamous cell
carcinomas (SCC), which develop from precursor squamous
intraepithelial lesions (SILs; Groves and Coleman, 2015). Vaccina-
tion against high-risk human papillomavirus (HPV), the necessary
cause of cervical SCC, is of no benefit to women who are already
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persistently infected with the virus (Stanley et al, 2014). Improved
understanding of cancer biology can be translated into new
treatments for cervical SCC, where novel targeted therapies would
be an important advance.
Early studies identified oncogenes of potential significance in
cervical SCC, by screening for genes located in regions of frequent
copy-number gain (CNG) that showed significant associations
between expression levels and copy number (Ng et al, 2007). One
of the most common regions of CNG in advanced cervical SCC is
on chromosome 5p, where a candidate driver gene is the
oncostatin-M receptor (OSMR), a cell surface cytokine receptor
that is suitable for antibody-mediated therapeutic inhibition
(Caffarel and Coleman, 2014). In our previous work, we observed
gain of the genomic locus containing OSMR in 61% of 36 cervical
SCC samples using array CGH and also found OSMR gain in 61%
of 110 independent cervical SCCs using fluorescence in situ
hybridisation (Ng et al, 2007). SCCs with OSMR CNG showed
significantly higher OSMR expression than those without CNG
(Po0.001; Ng et al, 2007). OSMR overexpression (which we define
as levels at least twofold greater than the mean of normal cervix
samples) was seen in 50% of 18 non-selected cervical SCCs
(Ng et al, 2007). Other groups independently showed chromosome
5p CNG in460% of advanced cervical carcinomas (Narayan et al,
2007; Scotto et al, 2008), while OSMR was overexpressed at
3.1-fold greater levels in 30 cervical carcinomas compared with 20
cases of normal cervical squamous epithelium (Scotto et al, 2008).
Importantly, we found that OSMR CNG was associated with
significantly adverse clinical outcome in cervical SCC, with a
relative risk of death vs cases without CNG of 3.6 (Ng et al, 2007).
In cervical SCC cells in vitro, OSMR overexpression conferred
greater sensitivity to the major ligand oncostatin-M (OSM), which
induced increased cell migration and invasion (without affecting
cell proliferation), plus an ability to induce angiogenesis (Winder
et al, 2011). Expression profiling of OSM-treated cell lines and
cervical SCC tissue identified consistent patterns of gene induction
following OSM:OSMR interactions, which led to functional
analyses of OSM-induced promalignant effects in cervical SCC
cells (Winder et al, 2011). We identified that one mechanism by
which OSMR confers increased motility and invasiveness to
cervical SCC cells is by inducing transglutaminase-2 (tissue
transglutaminase), which, among other functions, interacts with
cell surface integrin-a5b1 and fibronectin (Caffarel et al, 2013). In
the present study, we hypothesised that a further mechanism
mediating the promalignant effects of OSMR overexpression
in cervical SCC cells is induction of epithelial–mesenchymal
transition (EMT), a process linked with invasion and metastasis
(Polyak and Weinberg, 2009).
EMT is a dynamic and plastic mechanism that involves complex
transcriptional and post-transcriptional cellular changes (Craene
and Berx, 2013). These lead to downregulation of epithelial genes
and upregulation of mesenchymal markers, orchestrated through
EMT-associated transcription factors (EMT-TFs), including Snail,
Slug (Snail2), Zeb1 and Zeb2 (Lamouille et al, 2014). EMT is
characterised by changes in cell–cell contact, shape, motility and
invasiveness and may also be associated with the acquisition of
stem cell-like properties (Mani et al, 2008), including the ability to
grow as cell spheres in suspension culture. In carcinomas, EMT
and cancer stem cell (CSC)-like features are thought to arise
through common mechanisms of induction, including those
originating in the tumour microenvironment (TME; Korkaya
et al, 2011; Jung et al, 2015). We previously identified that OSMR
levels in SCCs correlated positively with those of fibronectin and
integrin-a5 (Caffarel et al, 2013), both regarded as mesenchymal
markers (Ocan˜a et al, 2012).
We investigated the functional associations between OSMR
overexpression and EMT by examining cervical SCC cells in vitro
and in preclinical metastasis models, and by analysing multiple
clinical sample data sets. Our evidence further supports therapeutic
targeting of OSMR in SCCs of the cervix and potentially other
anatomical sites.
MATERIALS AND METHODS
Tissue samples and gene expression profiles. All clinical tissue
sample sets studied are summarised in Supplementary Table S1.
We measured OSMR expression levels by qRT–PCR in: 13 cervical
SCCs and 3 samples of normal ectocervical squamous epithelium
(set 1; Scottish HPV Reference Laboratory, Edinburgh); 27 SCCs of
the larynx and 9 samples of normal larynx (set 2; CNIO Tumor
Bank Core Unit, Madrid, Spain); 18 skin SCCs and 7 samples of
normal skin (set 3; CNIO Tumor Bank Core Unit, Madrid, Spain).
All three tissue sample sets were studied with Local Research Ethics
Committee approval. In addition, we reanalysed our previous
microarray gene expression profiling of 32 samples of lesional
epithelium microdissected from cervical high-grade SILs (HSILs)
and low-grade SILs (LSILs) and 12 samples of normal ectocervical
squamous epithelium (set 4; Gene Expression Ommibus Accession
Number GSE27678; Ng et al, 2007; Winder et al, 2011; Caffarel
et al, 2013).
We also reanalysed published gene expression profiles from: 33
cervical SCCs plus 21 normal cervix (GSE9750, set 5; Scotto et al,
2008); 35 oral SCCs plus 6 normal oral mucosa samples
(GSE10121, set 6; Sticht et al, 2008); 31 tongue SCCs plus 26
normal tongue, including 20 matched sample pairs (GSE13601, set
7; Estilo et al, 2009); 13 vulvar SCCs plus 5 normal vulva
(GSE38230, set 8; Micci et al, 2013); 15 skin SCCs, 14 actinic
keratosis and 13 normal skin, including 13 matched sample pairs
(GSE32628, set 9; Hameetman et al, 2013); 5 skin SCCs, 4 actinic
keratosis and 6 normal skin (GSE2503, set 10; Nindl et al, 2006); 12
matched sample pairs of skin SCC and normal skin (set 11;
Hudson et al, 2010).
Analysis of next-generation sequencing data. We analysed
expression levels of OSMR and other EMT genes in the publically
available RNA sequencing results of The Cancer Genome Atlas
(TCGA). Computational analysis and statistical testing of the next-
generation sequencing (NGS) data were conducted using the R
statistical programming language. Filtered and log 2 normalised
RNA expression data, along with all available clinical data, were
downloaded from the GDAC firehose database (run:
stddata__2015_06_01) for each gene of interest from the CESC
(cervical cancer), HNSCC (head and neck squamous cell
carcinoma) and LUSC (lung squamous cell carcinoma) collections
(sets 12-14; Supplementary Table S1). Data downloads were
performed using the FirebrowseR database access R package.
Correlation testing for associations between expressed genes was
performed using the cor.test function in R, to calculate the
coefficient of variation (r) and test for significant deviation from no
correlation. A list of 16 EMT-related genes (Supplementary Table
S2) was derived from published literature (Polyak and Weinberg,
2009; Nieto, 2011; Craene and Berx, 2013; Lamouille et al, 2014).
Plotting of the correlation data was performed using the ggplot2 R
package. Survival analysis was performed using the survival R
package. Kaplan–Meier estimated survival curves were constructed
using the clinical data. Statistical testing of differences between
survival curves used the G-rho family of tests, as implemented in
the survdiff function of the survival package.
In addition, we analysed published NGS data from 24 cervical
SCC samples, in which the carcinoma and tumour-infiltrating cells
had been separated by flow sorting, followed by RNA sequencing
of the two cell populations (set 15; Supplementary Table S1; Punt
et al, 2015).
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Cells and cell culture. We used the representative OSMR
overexpressing cervical SCC cell lines CaSki (HPV16-positive)
and SW756 (HPV18-positive), in which OSMR was expressed at
3.4- and 4.5-fold greater levels than in a pool of four independent
cultures of basal-type normal cervical squamous cells (Ng et al,
2007). There was no overexpression of OSM in either cell. The cells
were obtained from the American Type Culture Collection
(ATCC-LGC, Middlesex, UK) and verified by short tandem repeat
profiling (Muralidhar et al, 2011). Cell culture and OSM treatment
were performed as described (Winder et al, 2011). OSM (R&D
Systems, Abingdon, UK) was added at 10 ngml 1, in accordance
with previous studies examining long-term effects of OSM in tissue
culture (Winder et al, 2011). OSM secretion into culture medium
was measured by sandwich ELISA (human OSM DuoSet ELISA,
R&D Systems), according to the manufacturer’s instructions.
Sphere forming assay. Cells in monolayer cultures were trypsi-
nised, filtered through a 30-mm filter (Sysmex, Milton Keynes, UK)
and resuspended in DMEM medium containing 1% methylcellu-
lose (R&D systems), 20 ngml 1 EGF and 20 ngml 1 b-FGF (both
PeproTech, London, UK). Cells were then added to non-adhesive
96-well plates (Greiner bio-one Cellstar, Monroe, NC, USA), at
1000 cells per well, and treated every three days with medium
containing 10 ngml 1 OSM, or control medium. The total
number of spheres in each well was counted after 10 days and
numbers in OSM-treated wells compared with those of control
wells. Spheres were then isolated by centrifugation and the RNA
extracted.
Real time quantitative PCR and western blotting. Relative
mRNA levels were measured by QuantiTect One-Step SYBR-
Green qRT–PCR (Qiagen, Crawley, UK) as described (Caffarel
et al, 2013), using the primers and conditions listed in
Supplementary Table S3. Expression ratios were calculated using
the comparative threshold cycle (Ct) method (Pfaffl, 2001) and
normalised using three housekeeping genes; ACTB, TBP and
HMBS (Vandesompele et al, 2002). Western blotting and
densitometry were performed as described (Caffarel et al, 2013),
using the primary antibodies listed in Supplementary Table S4. In
keeping with our previous work (Muralidhar et al, 2007;
Muralidhar et al, 2011; Winder et al, 2011), we defined OSMR
overexpression in SCCs as levels twofold or more greater than the
mean for corresponding normal cervical squamous epithelium
samples. The latter represented primary cultures for cell lines and
microdissected epithelium for tissues.
Generation of OSM overexpressing SW756 cells and bioluminescent
SW756 cells. SW756 cells were stably transfected with 2mg of
pUNO1-hOSM expression construct (InvivoGen, Toulouse,
France), using Lipofectamine LTX with PLUS reagent (Thermo
Fisher Scientific, Loughborough, UK) followed by Blasticidin
(InvivoGen) selection at 5mgml 1. Control transfections were
performed simultaneously using 2 mg of empty vector. For in vivo
experiments, bioluminescent SW756 cells were generated by stable
transfection of pGL4.51 luciferase reporter vector (Promega,
Southampton, UK), using Lipofectamine LTX with PLUS reagent
followed by G418 (Thermo Fisher Scientific) selection at
1.2mgml 1.
Small-molecule inhibition and RNA interference. Cells were
treated for 2 h with medium supplemented with TG101348 (Axon
Medchem BV, Groningen, The Netherlands), a small-molecule
inhibitor of JAK2. This was used at 1 mM, which was the lowest
concentration that showed inhibition of STAT3 phosphorylation
on western blotting. Negative control cells were treated with
equivalent volumes of DMSO vehicle (vol/vol) only.
STAT3 or OSMR were each depleted using four pooled siRNAs
(ON-TARGETplus SMARTpool L-003544 or L-008050 respec-
tively, both Dharmacon, Lafayette, CO, USA), compared with cells
treated with non-targeting control (NTC) pooled siRNAs
(siCONTROL non-targeting siRNA-1, Dharmacon). Individual
siRNAs were used at 10 nM, producing 40 nM pools. Cells were
transfected at 20–30% confluence using Lipofectamine RNAiMAX
(Invitrogen, Paisley, UK), as described (Hanning et al, 2013a;
Hanning et al, 2013b). OSM or PBS was added 24 h after
transfection and cells treated for 48 h.
Tail vein injection and subcutaneous xenografts. For experi-
mental metastasis experiments, bioluminescent SW756 cells
(1 106 in 100 ml) were injected into the lateral tail vein of
5–6-week-old female NOD SCID (NOD.CB17-Prkdcscid/NcrCrl)
mice (Charles River, Oxford, UK), using 29-gauge insulin needles.
Growth of lung tumours was monitored non-invasively using
optical whole-body imaging at weekly intervals. Mice were injected
with D-luciferin intraperitoneally and imaged 15min later using
the IVIS Spectrum preclinical imaging system (Perkin Elmer,
Waltham, MA, USA). Mice were treated three times a week with
intraperitoneal 100 ml injections containing 1 mg OSM or PBS only.
Animals were killed 11 weeks after tail vein injection and the lungs
examined histologically. The tissue samples were fixed in
4% formaldehyde in PBS and embedded in paraffin. Five-micron
sections were stained with H&E, observed with a DM LB light
microscope (Leica, Wetzlar, Germany) and photographed using a
DC500 digital camera (Leica).
To establish subcutaneous xenografts, 5–6-week old female
NOD SCID (NOD.CB17-Prkdcscid/NcrCrl) mice were implanted
subcutaneously in the flank with 5 106 bioluminescent SW756
cells. Mice were treated three times a week with peri-tumoural
injections of 100 ml containing 1mg OSM or PBS only. All mice
were palpated three times a week until tumours were detected
and thereafter tumours were measured with callipers. Tumour
volumes were calculated as (4p/3) (width/2)2 (length/2).
Animals were killed nine weeks after cell transplantation and
the subcutaneous tumours collected. Metastases in visceral
organs and brain were evaluated by quantification of biolumi-
nescent signal and by histopathology. To quantify skeletal
metastases, visceral organs were removed and the mice assessed
by optical imaging.
All mice were maintained in conventional cages within a specific
pathogen free animal facility. They were sacrificed by neck
dislocation. All animals were treated in strict accordance with
the local ethical committee (University of Cambridge Licence
Review Committee) and the UK Home Office guidelines.
Statistics. For comparisons between groups we used Student’s
T test and ANOVA, with post-hoc analysis by the Student–
Newman–Keuls’ test. Unless otherwise stated, results are expressed
as mean±s.e.m. Timecourses for the development of lung
metastases in vivo were compared using linear mixed effects
modelling, implemented in R via the lme4 package.
RESULTS
OSMR expression associates with EMT markers in cervical and
other SCCs. We used TCGA gene expression data for multiple
SCC sample sets to test for correlations between OSMR levels and
those of 16 genes associated with EMT (Supplementary Table S2).
In 251 cervical SCCs (sample set 12), we observed strong and
significant (Po0.05) correlations between OSMR and eight of the
16 genes, namely fibronectin (FN1), FOXC2, HMGA2, integrin-a5
(ITGA5), MMP10, Snail (SNAI1), Slug (SNAI2) and ZEB1
(Figure 1). Importantly, similar correlations were also seen in
SCCs from other anatomical sites. OSMR levels correlated with 14
of the 16 EMT genes in 514 head/neck SCCs (sample set 13) and
with all 16 genes in 492 lung SCCs (sample set 14) (Supplementary
Table S2).
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OSM induces EMT and CSC-like features in OSMR-overexpressing
cervical SCC cells in vitro. As SCC tissue samples include both
epithelial and stromal components, we used cervical SCC cells
in vitro (Ng et al, 2007) to investigate the direct associations
between OSMR overexpression and EMT. In both CaSki and
SW756, treatment with exogenous OSM at 10 ngml 1 for 72 h
induced a more mesenchymal morphology, with cell elongation,
reduced cohesion and a more refractile appearance on bright-field
microscopy (Figure 2A). Consistent with these changes, the OSM-
treated cells showed reduced mRNA and protein expression of the
epithelial marker E-cadherin (Figure 2B), together with increased
expression of fibronectin (Figure 2C), the EMT-TFs Snail and
ZEB2 (Figure 2D), and the matrix metalloproteinases MMP9 and
MMP10 (Figure 2E). The mesenchymal marker vimentin was also
induced in CaSki cells (Supplementary Figure S1). The effects
of OSM could be reduced or abrogated following depletion of
OSMR using pooled siRNAs (Supplementary Figure S1). SW756
cells that constitutively overexpressed OSM following stable
transfection also showed a more mesenchymal morphology,
identical to that of cells treated with exogenous OSM
(Supplementary Figure S2A), and also showed increased levels of
fibronectin, Snail, ZEB2, MMP9 and MMP10, compared with
control-transfected cells (Supplementary Figure S2B).
In addition, treatment with exogenous OSM increased the
formation of tumour spheres by SW756 cells grown in suspension
culture for 10 days (Figure 3A), consistent with increased CSC-like
properties (Wang et al, 2013). When compared with untreated
control spheres, the OSM-treated spheres showed increased levels
of Snail and ZEB2, as well as the pluripotency marker SOX2 and
OSMR itself (Figure 3B). The untreated spheres showed increased
levels of Snail and OSMR compared with SW756 cells in
monolayer culture. Untreated CaSki cells formed spheres very
efficiently and there were no additional effects of OSM treatment.
EMT induction requires JAK2/STAT3 signalling. As OSM:OSMR
interactions are known to induce STAT3 (Ng et al, 2007), we
tested the importance of JAK/STAT3 signalling in the induction
of EMT-related genes. To investigate the role of JAK2, cells
were treated with OSM for 15min, followed by assessment of
STAT3 phosphorylation by western blotting after 30min and
measurement of Snail transcript levels after 24 h. In this
experiment, cells pretreated with the small-molecule JAK2
inhibitor TG101348 for 2 h prior to the addition of OSM
showed reduced STAT3 phosphorylation and Snail induction
(Figure 4A). In addition, STAT3 depletion using pooled siRNAs
(Supplementary Figure S3) inhibited the induction of fibronectin
and Snail proteins following OSM treatment for 48 h (both
Figure 4B) and also inhibited expression of vimentin, ZEB2,
MMP9 and MMP10 in one or both of the OSMR overexpressing
cell lines (Figure 4C).
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Figure 1. Higher OSMR expression in cervical SCC tissue samples is associated with increased expression of mesenchymal markers. Linear
regression analysis of expression levels of EMT-associated genes versus OSMR in cervical SCC samples from TCGA (N¼251 maximum).
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Figure 2. OSM induces EMT in OSMR overexpressing cervical SCC cells. (A) Effects of OSM treatment (72 h) on the morphology of OSMR
overexpressing cells in monolayer culture. (B–E) Levels of EMT-associated markers in OSMR overexpressing cervical SCC cells treated with OSM
for the indicated time points, compared with control treated cells (C). Graphs show transcript levels and blots show protein levels. B, CDH1
(E-cadherin), C, fibronectin, D, EMT-TFs Snail and ZEB2, E, MMP9 and 10. Transcript quantification values are from three independent
experiments, whereas the western blots show the data from one representative experiment. The protein loading control was b-actin (lower row of
the blots). As the blots in C and D were done on the same membrane, the same loading controls are shown for each. *Po0.05, **Po0.01,
***Po0.001.
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OSM increases metastasis of OSMR-overexpressing SW756
cervical SCC cells in vivo. Mice injected intravenously with
luciferase-expressing SW756 cells and treated three times per week
with intraperitoneal OSM injections showed significantly increased
lung metastasis, compared with PBS-treated control animals
(Figure 5A and B). There were no histological differences between
the lung metastases seen in the two experimental groups (n¼ 5
mice per group; Figure 5C).
Subcutaneous xenografts of SW756 cells treated three times per
week with peri-tumoural OSM injections showed no difference in
growth rates compared with PBS-treated control xenografts (n¼ 4
per group; Figure 5D). There were no macroscopic or histological
differences between the primary xenografts from the two
experimental groups. However, the OSM-treated group showed
more skeletal metastases (n¼ 2 per group; Figure 5D). There was
no evidence of metastasis to other sites, including liver and lung.
OSMR is overexpressed in multiple SCCs and associated with
worse overall survival. In view of the effects of OSM:OSMR
interactions on metastasis in vivo, we investigated the frequency of
OSMR overexpression in SCCs, as well as the associations with
overall survival. When compared with equivalent normal tissues,
OSMR was overexpressed in SCCs from numerous sites, including
cervix, head/neck, vulva and skin (sets 1–3, 5–11) (Figure 6A–C;
Supplementary Figure S4). In cells flow-sorted from cervical SCCs
(set 15; Punt et al, 2015), OSMR was overexpressed by the
carcinoma cell fraction only, with very little expression in the
CD45þ tumour-infiltrating immune cells (Figure 6D). In contrast,
OSM was expressed strongly by the immune cells, with minimal
expression in the carcinoma cells (Figure 6D).
Lower-level increases in OSMR expression were also seen in
premalignant squamous lesions. In the cervix, there were gradual
increases in expression levels from normal cervix, through LSILs to
HSILs (set 4; Supplementary Figure S4B). OSMR overexpression
(levels at least twofold greater than the mean of the 12 normal
cervix samples) was seen in 3/21 HSILs, 0/11 LSILs and 0/12
normal cervix. In skin tissue, OSMR levels in actinic keratosis, a
potentially premalignant condition (Fu and Cockerell, 2003), were
intermediate between those of normal skin and cutaneous SCC
(sets 9 and 10; Supplementary Figure S4F and S4G).
We next examined the associations between OSMR expression
levels and clinical outcome, using cervical SCCs from TCGA. In
this analysis, we were unable to define OSMR overexpression by
reference to normal cervix samples, which were not included in the
data set. Accordingly, we divided the SCCs into two groups, those
with OSMR expression levels above the median for the data set
(n¼ 126) and those with expression levels at or below the median
(n¼ 125). Importantly, the SCCs with high OSMR expression
showed a highly significant adverse overall survival, compared with
those with low expression (P¼ 0.006; Figure 6E).
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This finding was confirmed in a small independent set of 13
cervical SCCs (set 1). Of these, seven (54%) overexpressed OSMR,
defined as levels at least twofold greater than the mean of the three
normal cervix samples in the data set. These seven SCCs showed
significantly worse overall survival than the six SCCs without
OSMR overexpression (Figure 6A). None of the three normal
cervix samples in this data set showed OSMR overexpression.
DISCUSSION
This is the first study to show that OSMR overexpression is
associated with EMT features and adverse clinical outcome in SCC
samples and that OSM can enhance EMT, CSC-like properties and
metastasis in SCC cells. We identified that OSMR is frequently
overexpressed in SCCs from multiple anatomical sites and provides
the malignant cells with increased responsiveness to the major
ligand OSM. The frequency of OSMR overexpression observed in
the cervical SCCs of sample set 1 (54%) was similar to our previous
observations in an independent data set (50%) (Ng et al, 2007). In
total, OSMR overexpression was present in 52% of the cervical
SCCs we examined (16/31), consistent with the observed frequency
of OSMR CNG (61%) and our evidence of significant associations
between gene copy number and expression (Ng et al, 2007; Winder
et al, 2011).
In cervical SCC samples, OSMR was almost exclusively
expressed by the carcinoma cells, while OSM was almost
exclusively expressed by the infiltrating immune cells. The latter
observation is consistent with evidence that OSM may be produced
by a wide range of cells in the TME, including macrophages,
dendritic cells and T-lymphocytes (Tanaka and Miyajima, 2003).
We previously demonstrated that OSM stimulation of OSMR
overexpressing cervical SCC cells leads to increased invasion and
migration in vitro (Winder et al, 2011). We now show that such
changes are accompanied by increased metastatic ability in vivo
and that EMT is an important association of these malignant
features.
Our present and previous (Caffarel et al, 2013) in vitro data
demonstrate that exogenous OSM rapidly induces a consistent
pattern of EMT-like changes in OSMR overexpressing cervical
SCC cells, with downregulation of E-cadherin and upregulation of
several mesenchymal markers. The latter include MMP9 and
MMP10, which are key mediators of ECM destruction during
carcinoma cell invasion (Nistico et al, 2012). All seven of the genes
that we tested and showed to be upregulated in the SCC cells
(fibronectin, MMP9, MMP10, Snail, vimentin, Zeb2 and integrin-
a5 (Caffarel et al, 2013)), also showed significant positive
associations with OSMR levels in one or more of the TCGA SCC
tissue data sets (Figure 1; Supplementary Table S2). We concluded
that the correlations between OSMR and multiple mesenchymal
markers in clinical samples are likely to include direct effects on the
carcinoma cells. However, contributions to these observations from
cells of the TME cannot be excluded.
The effects of OSM treatment of OSMR overexpressing SCC
cells also included increased CSC-like features, as measured using
suspension cultures. The spheres formed by OSM-treated cells
showed increased expression of mesenchymal genes, as well as the
pluripotency marker Sox2, similar to observations in breast
adenocarcinoma cells (West et al, 2014). Interestingly, OSMR
was overexpressed in untreated cell spheres, compared with cells in
monolayer culture, and was further induced by OSM. Altogether,
these data indicate that OSMR is directly linked with CSC-like
properties in cervical SCC cells. As EMT is a dynamic, reversible
process (Thiery et al, 2009), reversion of OSM-exposed SCC cells
to a more stem-like state would support clonal expansion and the
development of tumour heterogeneity, within both primary lesions
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and metastatic deposits. It might also be expected that high levels
of OSMR and/or OSM in SCCs would confer resistance to
chemotherapy and radiotherapy (Nieto, 2011). Indeed, this effect
may have contributed to the association between OSMR levels and
adverse clinical outcome that we observed in multiple cervical SCC
data sets, including TCGA samples.
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The enhanced responsiveness to OSM in OSMR overexpressing
cervical SCC cells is associated with induction of multiple
signalling pathways, including phosphorylation of STAT3
(Ng et al, 2007). Our present data indicate that STAT3 is important
in inducing mesenchymal markers and the major EMT-TF Snail.
One mediator of STAT3 phosphorylation is JAK2, as indicated by
specific small-molecule inhibition. It is likely that other signalling
pathways induced by OSM in OSMR overexpressing SCC cells are
also of functional significance. In breast adenocarcinoma, MAPK
signalling is associated with downregulation of oestrogen receptor (an
epithelial marker; West et al, 2012) and PI3K signalling with
increased CSC-like properties (West et al, 2014). Detailed dissection
of the roles of signalling pathways in the multiple promalignant
effects of OSM in cervical SCC cells is now required.
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There are likely to be multiple effectors of the transcriptional
changes characteristic of EMT. Our current data, from in vitro
experiments and clinical samples, indicate a role for the EMT-TFs
Snail, Slug, ZEB1 and ZEB2. It will now be important to
investigate the mechanisms responsible for the induction of these
EMT-TFs, including similarities and differences with other
cell types. For example, the OSMR target transglutaminase-2
(Caffarel et al, 2013) has been linked to EMT in ovarian
malignancy (Shao et al, 2009) and may also have a role in SCCs.
In breast adenocarcinoma cells OSM induces Lin28, which
represses Let7 microRNAs and so upregulates protein-coding
gene targets including HMGA2 (Guo et al, 2013). The latter is a
non-histone chromatin protein that acts as an architectural
transcription factor and is known to bind the SNAI1 promoter
(Thuault et al, 2008). Whether similar mechanisms apply in
tumours of squamous histogenesis remains to be determined,
particularly given the lineage specificity of microRNA profiles
(Lu et al, 2005). However, we note the significant correlations
between levels of OSMR and HMGA2 across the TCGA
SCCs (Figure 1 and Supplementary Table S2). There may also
be differences in mechanisms of EMT induction in SCCs at
different sites. For example, OSMR levels correlated with some
EMT markers (e.g., Twist2 and MMP2) in head/neck and lung
SCCs but not cervical SCCs, while the high-risk HPV oncogenes
E6 and E7 that drive cervical and some head/neck SCCs have
been linked with EMT induction (Qureshi et al, 2015).
Our in vivo data indicate that the metastatic capacity of OSMR
overexpressing cervical SCC cells increases following exposure to
OSM, as assessed by a lung colonisation assay. This demonstrates
an important role for OSMR early in the metastatic process, for
example via increased extravasation and infiltration of secondary
sites (Nguyen et al, 2009). We observed no histological differences
between the lung metastases at the end of the experiment,
consistent with the reversibility of EMT, via the reciprocal process
of mesenchymal–epithelial transition (Brabletz, 2012). In mice
bearing cervical SCC xenografts, the increased skeletal metastases
may have been due to several consequences of OSM:OSMR
interactions, including enhanced cell motility/detachment, inva-
sion, blood vessel intravasation and extravasation/colonization
(Nguyen et al, 2009; Caffarel and Coleman, 2014). Our
observations support the clinical evidence that OSMR over-
expression in cervical SCC is associated with significantly worse
overall survival, as well as with gene expression profiles indicating
EMT. These data resonate with those in breast adenocarcinoma,
where high OSMR expression correlates with shorter overall
survival and recurrence free survival, together with features of
EMT (West et al, 2014). Recently, evidence for an association
between OSMR overexpression and adverse outcome has also
been identified in a non-epithelial malignancy, glioblastoma
multiforme (GBM), again with evidence of an association with
EMT (Natesh et al, 2015).
Our data have indicated an important mechanism by which
OSMR overexpression provides a selective advantage in cervical
SCCs. Cells capable of greater migration/invasion are more likely
to access conditions of improved oxygenation and nutrient
availability and would therefore be provided with a competitive
advantage in mixed cell populations. Induction of EMT/CSC-like
properties increases metastasis and therapeutic resistance (Polyak
and Weinberg, 2009), both of which are likely to contribute to the
adverse clinical outcome associated with OSMR overexpression in
cervical SCC. Together, our findings further strengthen the case for
inhibiting OSM:OSMR interactions as a targeted anti-cancer
therapy (Caffarel and Coleman, 2014). The observation that
OSMR is commonly overexpressed in a range of SCCs, as well as
other carcinomas and GBMs, indicate that effective targeting of
this promalignant pathway may produce clinical benefits in a wide
range of common cancers.
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